ADVENT Post-Approval Study

Eligibility Criteria

• * Subjects with drug-refractory, recurrent, symptomatic paroxysmal atrial fibrillation (PAF) who are indicated for a treatment with the FARAPULSE Pulsed Field Ablation (PFA) System\*; (Subjects refractory, or intolerant or contraindicated to at least one class I or III antiarrhythmic medication or contraindicated to any class I or III medications.)
• * Subjects who are willing and capable of providing informed consent;
• * Subjects who are willing and capable of participating in all testing and follow-up associated with this clinical study at an approved clinical investigational site;
• * Subjects who are of legal age to give informed consent specific to the national law.
• * For the LUX-Dx Sub-Study: Subjects with an existing LUX-Dx Insertable Cardiac Monitor (ICM), inserted ≥ 180 days prior to enrollment, or having a LUX-Dx ICM inserted per the investigator's standard of care, up to 7 days after the ablation procedure. Subjects with or having a LUX-Dx ICM inserted per standard of care, up to 7 days after the ablation procedure.
• * Subjects with any known contraindication to an AF ablation or anticoagulation, including those listed in the Instructions For Use (IFU);
• * Subjects with any prior left atrium (LA) ablation;
• * Subjects who may need an ablation in the left atrium besides PVI, such as for left-sided atrioventricular reentrant tachycardia (AVRT), left-sided atrial tachycardia (AT) or atypical left-sided atrial flutter (AFL);
• * Women of childbearing potential who are or plan to become pregnant during the time of the study (assessment per investigator's discretion);
• * Life expectancy of \< 1 year, per investigator's medical judgement.